Creating a database for patients at risk of interstitial lung disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to establish a clinical database for patients who are at risk for interstitial lung disease (ILD) and to implement a prospective screening program for early detection of ILD. Participants will undergo chest CT scans to monitor their lung health. The study will collect data to better understand the progression of ILD in patients with known systemic diseases that predispose them to this condition. By gathering this information, researchers hope to improve early diagnosis and management of ILD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age: ≥ 18 years
* patients with a known systemic disease bearing a risk for ILD
* signed informed consent (for prospective part)

Exclusion Criteria:

* Age \< 18 years
* comorbidities severely limiting life-expectancy (e.g. severe cardiovascular conditions, malignant disease)

Where it's running

• Medical University of Graz, Department of Internal Medicine, Division of Pulmonology
  Graz, Austria Recruiting

Study contacts

• Study coordinator: Gabor Kovacs, MD
• Email: gabor.kovacs@klinikum-graz.at
• Phone: +43-316-385

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TX000045 for pulmonary hypertension from interstitial lung disease

  This study tests TX000045 to see if it can reduce pulmonary vascular resistance in people with PH caused by interstitial lung disease and to check its safety.

  Recruiting at 12 sites Phase 2 Tectonic Operating Company, Inc. · Phoenix, Arizona and 15 other locations · NCT07473700

• Nebulized human amniotic fluid for interstitial lung disease

  This pilot will try nebulized diluted human amniotic fluid (HAF‑Matrix) in adults 40–90 with interstitial lung disease to check safety and look for early signs of benefit.

  Recruiting Phase 1 Maule Stem Cell Research Institute, Inc. · Venice, Florida · NCT07372989

• Evaluating Belimumab for Lung Disease Linked to Autoimmune Conditions

  This study is testing if the medication belimumab can help adults with lung disease caused by autoimmune conditions feel better and breathe easier.

  Recruiting at 126 sites Phase 3 GlaxoSmithKline · Los Angeles, California and 131 other locations · NCT06572384

• Evaluating Olokizumab for Progressive Fibrosing Lung Diseases

  This study is testing if a new injection called olokizumab can help people with progressive fibrosing lung diseases breathe better and improve their overall health compared to a placebo.

  Recruiting at 33 sites Phase 2/3 R-Pharm · Barnaul and 32 other locations · NCT06440746

• Testing hymecromone in adults with interstitial lung disease

  This study is testing a new medication called hymecromone to see if it can help adults with progressive interstitial lung disease feel better and improve their lung function.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Research Triangle Park, North Carolina · NCT06325696

• Digital self-management package for people with interstitial lung disease

  This study is testing a new smartphone app designed to help people with interstitial lung disease manage their health better and feel improved overall compared to standard care.

  Recruiting at 4 sites University of Sydney · Sydney, New South Wales and 3 other locations · NCT06122233

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.